Seattle Genetics outlook still positive, says RBC Capital

Seattle Genetics downgraded at BofA/Merrill As previously reported, BofA/Merrill downgraded Seattle Genetics to Underperform from Neutral. The firm said AETHERA data for interim overall survival advantage was not significant and could reinforce Adcetris' role as a salvage therapy as opposed to a frontline option.

http://ift.tt/YGVWbl